In vivo fluorescence flow cytometry reveals that the nanoparticle tumor vaccine OVA@HA-PEI effectively clears circulating tumor cells
作者机构：The Department of Biomedical Engineering Institute of Advanced Clinical MedicinePeking University Beijing 100191P.R.China Institute of Medical Technology Peking University Health Science Center Beijing 100191P.R.China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Peking University Cancer Hospital&InstituteBeijing 100142P.R.China School of Instrument Science and Opto-Electronics Engineering Beijing Information Science&Technology University Beijing 100192P.R.China
出 版 物：《Journal of Innovative Optical Health Sciences》 (创新光学健康科学杂志（英文）)
年 卷 期：2024年第17卷第6期
页 面：107-123页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported by the National Key Research and Development Program of China,Grant Number:2021YFF0502900,2019YFC1604604 National Natural Science Foundation of China,Grant Number:62075013,62027824
主 题：Tumor vaccines circulating tumor cells in vivo fluorescence flow cytometry.
摘 要：Tumor vaccine therapy offers significant advantages over conventional treatments,including reduced toxic side ***,it currently functions primarily as an adjuvant treatment modality in clinical oncology due to limitations in tumor antigen selection and delivery *** vaccines often fail to elicit a sufficiently robust immune response against progressive tumors,thereby limiting their clinical *** this study,we developed a nanoparticle-based tumor vaccine,OVA@HA-PEI,utilizing ovalbumin(OVA)as the presenting antigen and hyaluronic acid(HA)and polyethyleneimine(PEI)as adjuvants and *** formulation significantly enhanced the proliferation of immune cells and cytokines,such as CD3,CD8,interferon-,and tumor necrosis factor-,in vivo,effectively activating an immune response against B16–F10 *** vivofluorescenceflow cytometry(IVFC)has already become an effective method for monitoring circulating tumor cells(CTCs)due to its direct,noninvasive,and long-term detection *** study utilized a laboratory-constructed IVFC system to monitor the immune processes induced by the OVA@HA-PEI tumor vaccine and an anti-programmed death-1(PD-1)*** results demonstrated that the combined treatment of OVA@HA-PEI and anti-PD-1 antibody significantly improved the survival time of mice compared to anti-PD-1 antibody treatment ***,this combination therapy substantially reduced the number of CTCs in vivo,increased the clearance rate of CTCs by the immune system,and slowed tumor *** greatly enhance the clinical application prospects of IVFC and tumor vaccines.
维普期刊数据库
